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Abstract. Spectrophotometric heparin assays are expected to be independent on clotting
factors, either activated or nonactivated, but could be sensitive to heparin neutralization dur-
ing blood collection. Is was shown that more than 200 U of heparin/l plasma can completely
be neutralized during blood processing. Because the heparin neutr"alization is not constant but
dependent on the sample as well as on the type of sample handling, one cannot beforehand
compensate and correct the results for possible heparin neutralization. We tested the use of
pyridoxal 5'-phosphate (PLP) to prevent heparin neutralization. As the use of PLP in the
citrate tube decreased the heparin neutralization to a negligible effect, PlP-citrate tubes are to
be preferred for all plasma heparin determinations.
Introduction
Heparin treatment is monitored by exam-
ining blood samples of treated patients. The
activity of heparin can be estimated by co-
agulation tests [1, 2] or by amidolytic chro-
mogenic substrate assays [3]. Clotting assays
may show a large interindividual difference
in heparin response [4, 5] and a large depen-
dency on the reagents used [6, 7]. The hepa-
rin concentration accurately measured by a
chromogenic substrate assay is assumed to
represent the heparin concentration in vivo.
It is well known that the results of clotting
assays could be influenced by activation of
clotting factors and by neutralization ofhep-
arin during blood processing. Actions gener-
ally taken to ensure correct results are: reject-
ing the first volume of blood obtained, chill-
ing and direct processing ofthe sample. Spec-
trophotometric heparin assays are expected
to be independent on clotting factors, either
activated or nonactivated. but could be sensi-
tive to heparin neutralization [8].
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Several measures were suggested to pre-
vent release of heparin-neutralizing agents,
notably platelet factor 4 Of a) [9-l l]. Mix-
tures of drugs are used to prevent the release
of pf4 from thrombocytes [10-14]. Even
then, special measures like direct processing
of samples collected on melting ice are re-
quired.
The influence of the two-syringe method
was investigated by determining the APTT,
the antithrombin III (AI-IID and the heparin
concentration in the first tube and in the sec-
ond tube ofblood collected from patients on
heparin therapy. The influence ofblood stor-
age and chilling of the centrifuge were each
investigated by determining the heparin neu-
tralization capacity of plasma diflerently ma-
nipulated.
As pyridoxal phosphate (PLP) has been
reported to inhibit platelet functioning [15],
we studied whether this drug could be used to
preyent heparin neutralization. The experi-
ments were repeated with PLP containing
blood collection tuhes. The heparin concen-
tration in plasma of the first PLP tube was
compared with the heparin concentration in
the generally used second citrate tube.
Materials and Methods
Reagents
Heparin: 5,000 USP U/ml of the sodium salt
(thromboliquine, Organon Teknika, Oss, The Nether-
lands). Dilutions were made with buffered saline (147
mM NaCl, 6.52 mM NazHPOn, 1.62 mM KHzPOr,
pH 7.35).
Thrombin (Roche, Basel, Switzerland), contained
per vial 120 USP U bovine thrombin. The contents of
each vial were dissolved in 2.4 ml distilled water.
Before use, 1 vol ofthrombin was diluted with 5 vol of
buffer.
Antithrombin III KabiVitrum, Amsterdam, The
Netherlands) contained l0 U/vial. I U is defined as
the activity found in I ml plasma. The contents ol
each vial were dissolved in 10 ml distilled water and
100 pl heparin (2,500 U4) were added to titrate the
heparin neutralization effect [16].
Factor Xa (KabiVitrum): the contents of each vial
(71 nkat) were dissolved in l0 ml distilled water.
Chromogenic substrates: benz-I1e-Glu-Gly-Arg-
pNA'HCl (3-2222) and H-D-Phe-Pip-Arg-pNA'2
HCI (5-2238) (KabiVitrum), and Chromozvm-Th
(Boehringer-Mannheim, Amsterdam) were each dis-
solved in distilled water.
Buffer (pH 8.4 and I 0.2) contained di-Na-EDTA
(7.5 mM, Tris-HCl (50 mM) and NaCl (175 nM.
APTT reagent: DiagenKaolin - platelet substitute
from Diagnostic Reagents Ltd', Thame, Oxon, UK.
Pyridoxal 5'-phosphate was obtained from Merck,
Darmstadt (Pyridoxal-5'-Phosphorsiiureester-Mono-
natriumsalz (CaHqNNaOeP'HzO, MW 269). 1.346 e
was dissolved in 20 ml distilled water to obtain
0.25 M.
Citrate tub€: 2.0 ml Venoject tube (black stopper)
containing 8.2 ml 3.80/o tri-Na-citrate.
PLP tube: 50 Uf 0.25 MPLP solution was added to
a citrate tube after removing the stopper. The stopper
was replaced and the original vacuum was restored by
means ofa vacuum pump. This tube used in a vacuum
system, was filled to the same height as the original
tube.
Sample procedure.'blood was drawn from the ante-
cubital vein by means of a vacuum system with a mul-
tisample needle. This sample is referred to as the first
tube. Next, the second tube was drawn. Unless stated
otherwise, samples were centrifuged for 10 min at
3,500 g at 15'C. Plasmas thus obtained contained
fewer than 3 X 10e platelets/l, and were stored at
-20'C. The delay between venipuncture and centrifu-
gation was less than l5 min for plasma pool as well as
for specimens from outpatients. For inpatients this
delay was Vz-2 h.
Pooled citrate plasma: contents ofthe second tubes
of citrated plasmas from 31 donors were centrifuged
twice at 3,500sr at 15 "C, subsequently mixed and
stored at -70 "C in aliquots of I ml. The donors were
laboratory workers, about as many males as females
with a mean age of 30 years, healthy and using no
drugs.
Pooled PLP plasma: the same procedure as de-
scribed above was used to prepare a pool ofPLP plas-
ma, obtained in the first PLP tube from the same
donors.
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Assays
Automated chromogenic heparin assays were per-
formed on a Corona batch analyzer (Clinicon, Amster-
dam) as described before [16] with3-2222 and factor
Xa, as well as with Chromozym-Th or 5-2238 and
thrombin. Reference samples were made of pooled
citrate or PLP plasma spiked with known amounts of
heparin of the same batch as we would determine. The
calibration curve was a logarithmic lit through the ref-
erence measurements. The activated partial thrombo-
plastin time (APTT) was performed as indicated by
the manufacturer of the reagent, on a 'KCl0' coagu-
lometer (Salm & K-ipp, Breukelen, The Netherlands).
Plasma was incubated with the APTT reagent in a
plastic tube. After recalcification the clotting time was
measured.
Heparin-Neutralizing Capacity (HNC)
To determine the HNC, 100 U/l heparin were
added to the PLP plasmas (in duplicate) at the predi-
lution stage ofthe heparin assay. To the non-PLP plas-
mas, 200 U/l heparin were added. Anti-IIa activity of
the heparin concentration was determined using a ref-
erence curve from 0 to 200 U/1. The dilference be-
tween the amount of heparin added and of heparin
found was considered to indicate the amount ofhepa-
rin neutralized (HNC). Therefore, the HNC of the
pooled plasma used for reference measurements was
zero by defrnition. Automated spectrophotometric At-
III assays were performed on the same analyzer, as
described [16] with 5-2222 ar'd factor Xa, as well as
with Chromozym-Th or 5-2238 and thrombin.
Experimental Procedures
Comparison of the First and Second Sample Tubes.
Samples obtained from inpatients receiving heparin
were processed as described above. Citrate plasmas
obtained in the first and second tubes, both being non-
PLP citrate tubes, were compared with regard to the
APTT and to the anti-Ila and anti-Xa activities of
heparin and ATIII. Plasmas obtained in the first PLP
tube and the second citrate tube were compared with
regard to the anti-Ila and anti-Xa activity of heparin.
PLP plasmas obtained in the first and second tubes
from healthy laboratory workers and outpatients not
receiving heparin were used to compare the HNC.
Influence of Delay on the HNC. Citrated blood was
obtained from 20 outpatients not receiving heparin
treatment. Blood from the Iirst tube was distributed
over two plastic tubes. One tube was centrifuged at
I 5 'C within I 5 min after sampling, whereas the other
tube was centrifuged after leaving the blood for 5 h at
room temperature. Plasmas were stored at -20 "C till
HNC was determined. Reference samples for the
HNC assay were made with pooled citrate plasma.
This experiment was repeated with PlP-citrate plas-
ma, obtained from another 20 outpatients not receiv-
ing heparin. In the HNC assay, reference samples
made with PLP plasma were used.
Statistics
In the calculations ofthe relationship between two
methods the experimental variance (determined in
day-to-day reproducibility tests) of both methods was
taken into account [7]. The influence ofdelay and of
temperature control in the centrifuge on the HNC of
plasma from first tubes was investigated in a balanced
experiment, using paired samples of 20 patients. Ex-
periments were designed to trace the components
which were to influence the recovery of heparin: S e -
the random experimental error ofthe heparin determi-
nation, derived from earlier experiments; S i - the ran-
dom inter-sample variance in HNC; A - the ellect of
each type of sample handling; S i.a. - the composed,
inter-sample effect of each type of sample handling.
The contribution of each component to the total
variance of the HNC was analyzed. A hierarchical
two-by-two analysis of variance (factor I = eflect of
sample handling; factor 2 = samples) was applied.
Whether the influence of the process on the HNC is
also sample dependent was revealed by this analysis as
well. No effort was made to dilferentiate between
interindividual and intervenipuncture variation. Both
factors compose the intersample variation.
Results
The effect of the two-syringe technique
was analyzed for the APTT, the heparin and
AI-III concentration (table I). The AI-III
concentrations in first and second tube ci-
trate plasmas proyed to be similar (fig. l).
The APTT of first tube citrate plasma was
about 200/o shorter than the APTT of second
tube citrate plasma (fie.2). About I2o/o of the
anti-Ila (fig. 3) as well as anti-Xa (fig.4) ac-
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Table I. Comparison offirst and second citrate tubes
Assay Activity S a S b
Heparin
Heparin
Heparin
At-III
At-III
APTT
anti-IIar
anti-IIa2
anti-Xa
anti-IIar
anti-IIa2
-6 U/1
-4 U/l
-4 U/l
-5o/o
-6o/o
4 s
T1 U/ \
l0 u/l
t4 u/l
4o/o
3o/o
7 s
0.883
0.883
0.883
1.05 NS
r.05 NS
0.773
0.03
0.03
0.03
0.05
0.04
0.04
0.94
0.98
0.93
0.91
0.92
0.87
68
65
65
69
69
68
Relationships (y = a + b.x) between results of frrst tube citrate plasma (y) and results of second tube citrate
plasma (x). The standard deviation of intercepts (S a) as well as of the slopes (S b) are given. The last column
shows the correlation coefftcient (r).
I Substrate: 5-2238.
2 Substrate: chromozym-Th.
3 The slope does differ significantly from 1.00 (p < 0.005). NS = not significant.
tivities of heparin in first tube citrate plasmas
appeared to be lost in comparison to those in
second tube citrate plasmas.
The HNC were determined in citrate plas-
mas processed in well-defined conditions to
analyze the contribution of the discrete steps
to the heparin neutralization. It appeared that
more than 200 U/l may be neutralized (ta-
ble II). By analysis of variance it is found that
the large variance in the HNC (e.g. 78 U/l) is
mainly due to the large intersample variance
(S i = 70 U/l) and not to the relative small
experimental variance (S e = 15 U/l). The evi-
dent contribution of the composed intersam-
ple effect (S i.a.) revealed that this eflect was
not constant, but significantly (p < 0.001)
dependent on the individual samples.
It was assumed that heparin neutraliza-
tion during blood handling would be pre-
vented if platelet activation could be inhibit-
ed. Platelet activation by ristocetin could be
inhibited by small amounts of PLP. The PLP
concentration used was limited by the extinc-
tion of PLP plasma during the measurement.
We repeated the experiments described
above with PLP specimens. From the results
in table II, it is obvious that under the condi-
tions tested the HNC of PLP tubes are far less
than the HNC in citrate tubes. MoreoYer, the
influence of sample handling is reduced enor-
mously in the presence of PLP. Although for
the PLP tubes a statistically significant in-
fluence of the sample handling method is still
shown, the mean difference is of the same
order as the experimental error and appeared
to be independent on the individual samples
(S i.a. = NS). Also the large individual contri-
butions to the total variances of the HNC in
the citrate tubes (70 and 57 U/l) are reduced
to clinically negligible values (18 and 9 U/l)
in the PLP tubes.
The heparin neutralization in PLP plas-
mas of second tubes of 3 t healthy individuals
appeared to be 26 + 16 U/l higher than in
I7
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Fig. 1. Relationship between AI-III
concentrations in first tube citrate plasma
(y-axis) and in second tube citrate plasma
(x-axis), determined with the AI-III assay
(witlt chromozym-Th) based on IIa inacti-
vation.
Fig. 2. Relationship between the APTT,
determined in the lirst tube citrate plasma
(y-axis) and in the second tube citrate
plasma (x-axis).
Fig.3. Relationship between anti-Ila
(chromozym-Th) activity of heparin in the
first tub€ citrate plasma (y-axis) and in the
second tube (x-axis).
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Table II. HNC in different conditions
Sample handling Analysis of variance
S eS i S i .a.
Delay
r 20 (78)
2 (te)
183 (67)
1 0  ( 1 e )
5 h0 h
RT
63r
8*
70*
l8 *
57*
9*
24*
NS
t 5
8
1 1
8
Centrifuge
4 " C
+
l  18  (6 r )
-4 (e)
The HNC in U/l in first tube samples processed in different conditions. The mean ( t I SD) HNC of 4 groups
of20 samples is given for each type ofhandling. Signihcant contribution ofthe diflerent components to the total
variance of HNC is indicated by an asterisk (p < 0.001)'
- = Citrate tube without PLP; HNC relative to citrate pool; * = PLP tube; HNC relative to PLP pool; RT =
nonchilled, room temperature or higher.
r48 (65)
3 (13)
34
NS
30*
7*
PLP plasmas of first tubes. Therefore we used
a pool of these first samples as reference
material. The difference in HNC between
first and second PLP tubes of 17 outpatients
is not significant (5 t l5 U/D. The difference
between first and third PLP tubes (10 + l l
U/l) is statistically significant (p < 0.001)
in a paired t test, but for clinical use negli-
gible.
We compared the anti-ila activity of hep-
arin in first tube PLP plasma with second
tube citrate plasma for inpatients receiving
heparin. As heparin up to 200 U/l could be
neutralized completely, we omitted data
points at heparin levels lower than 200 U/l
PLP plasma in the calculation of the regtes-
sion line (fig. 5).The heparin concentration is
7 2 + 23 U/l higher in PLP plasma (first tube)
than in citrate plasma (second tube).
Discussion
To investigate the necessity of applying
the two-syringe technique in obtaining blood
for heparin assay, we compared the results of
heparin determinations in the first and the
second tubes of blood collected. We found a
difference between the influence on APTT
and on heparin levels spectrophotometrically
determined. Neutralization of heparin by pf 4
from platelets in the Iirst tube may explain
that heparin concentrations found are be-
tween 94 and 9l o/o of the concentration
found in the second tube. The larger devia-
tion in the APTT may be explained by the
additional effect of the activation of clotting
factors in the frrst tube. This activation does
influence clotting assays, but will not affect
spectrophotometric heparin assays. This
Iiit;F€tt-€€€i=-':.t.::.,+=r,.aiEia*-{l
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Fig.4. Relationship between anti-Xa
(3-2222) actlity of heparin in the first tube
citrate plasma (y-axis) and in the second
tube citrate plasma (x-axis).
400
Fig.S. Relationship between anti-Ila
(5-2238) activity of heparin in hrst tube
PLP plasma (y-axis) and in second tube
citrate plasma (x-axis). Only data points
with more than 200 U/l PLP plasma are
shown.
again illustrates that the APTT cannot be
used to quantify validly heparin concentra-
tions. It is clear that less heparin is recovered
in the first tube than in the second tube. The
diflerence in heparin concentrations cannot
be explained by a difference in At-III concen-
tration, as AI-III concentrations of both
tubes were the same (fig. l). The degree of
heparin neutralization induced by various
sample handling procedures was further in-
vestigated with the pooled, promptly pro-
cessed and chilled second tube samples as a
standard. The HNC appeared to be 120 t 78
U/l in the first tube. If first tubes are used for
heparin determination, tle heparin concen-
tration found will be lowered by L20 Ull
average. As delay in processing the blood
after venipuncture cannot always be avoided
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in routine practice, this figure may rise to
above 180 U/l.If a nonchilled centrifuge is
used, the heparin concentrations found may
be lowered by an extra 30 U/l average.
Because the HNC is not constant, but de-
pendent on the sample as well as the type of
sample handling, one cannot beforehand
compensate and correct the results for possi-
ble heparin neutralization. Therefore the
heparin concentration measured, especially
in the range from 0 to 200 U/1, cannot relia-
bly represent the intravascular heparin con-
centration, unless heparin neutralization can
be prevented. Heparin is probably neutral-
ized mainly by pf 4 released from the alpha
granules of platelets during blood processing
[8, 9, l8]. In order to prevent release of mate-
rial from these granules, the use of mem-
brane-stabilizing drugs in addition to an anti-
coagulant has been studied before I ll. PLP
has been reported to inhibit platelet function-
ing [5] and even its use as an anticoagulant
has been described [19]. We added PLP to
citrate tubes for blood collection, to prevent
release ofpf4 and expected reduced neutral-
ization of heparin. The use of PLP decreases
the heparin neutralization tremendously.
Hardly any influence of sample handling or
intersample variance can be shown in PLP
tubes in comparison to the large influences
on the HNC in citrate tubes. Based on the
results of the HNC tests we consider the PLP
tubes superior to the citrate tubes in blood
collection for heparin determination. Pre-
sumably as a result of the longer period of
increased pressure applied by the tourniquet
used, the HNC is little higher in the second or
third than in the first tube ofblood collected
from the same venipuncture wound. This
phenomenon suggests an advantage of using
the hrst tube rather than the second for hep-
arin determination. The heparin concentra-
tion in the currently used second tube citrate
plasma in about 72 U/l plasma lower than
the concentration in first tube PLP plasma.
The unpredictable variation in heparin neu-
tralization in citrate plasma may also cause a
variation in the APTT, which limits the
value of the APTT.
For the heparin determination, reference
samples were used made from pooled PLP or
citrate plasma spiked with heparin. The
HNC of pooled plasma used is zero by defi-
nition. Plasma pools are made in the labora-
tory, where the delay between the venipunc-
ture and centrifugation is 20 min at the most.
Routine blood collection in the hospital takes
a delay of 90 min as ayerage. Samples taken
on PLP show no influence of delay while
samples in citrate tubes show an unpredicta-
ble variation in heparin neutralization. Thus
we hnd no diflerence in heparin concentra-
tion between pool and patients where it con-
cerns PLP samples and about 72U/l differ-
ence where it concerns citrate samples.
Therefore, the latter should not be used for
monitoring heparin therapy.
In conclusion it can be said that the use of
PLP decreases the heparin neutralization to a
negligible effect. For collection and storage
(up to 5 h) of the sample no melting ice is
necessary. The possibility of using the hrst
tube implies that only one tube needs to be
drawn for heparin determination. The use of
PLP in the citrate tube for blood collection is
preferred for all plasma heparin determina-
tions.
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